Altoida

OverviewSuggest Edit

Altoida develops and markets a healthcare platform and application for Alzheimer’s patients. Altoida Medical Device (AMD) is a class II medical device to screen and monitor cognitive outcomes. It supports neurologists to classify patients healthy, at risk, and with Mild Cognitive Impairment (MCI) as a digital biomarker.

TypePrivate
Founded2016
HQLuzern, CHMap
Websitealtoida.com

Recent NewsAll News

Latest Updates

Employees (est.) (Nov 2021)18(+6%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Altoida

Richard Fischer

Richard Fischer

Founder & CEO
Ioannis Tarnanas

Ioannis Tarnanas

Founder & CSO
Maximilian Buegler

Maximilian Buegler

Founder & CTO
Show more

Altoida Office Locations

Altoida has offices in Luzern and Suwanee
Luzern, CH (HQ)
Professuren der Kultur-und Sozialwissenschaftlichen Fakultät 31 Hirschengraben
Suwanee, GA, US
4315 Alta Dr #1402
Show all (2)

Altoida Financials and Metrics

Summary Metrics

Founding Date

2016

Altoida total Funding

$7.5 m

Time since last funding

2 years ago

Altoida investors

Polytech Ventures, Philipp Stauffer, Fyrfly Venture Partners, Hikma Ventures, Grey Sky Venture Partners, M Ventures, Adrian Locher, VI Partners AG, Alpana Ventures
Show all financial metrics

Altoida Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

Altoida Online and Social Media Presence

Altoida's Trends

Embed Graph

Altoida News and Updates

January 14, 2020

Altoida Chief Science Officer Ioannis Tarnanas to Keynote at Worldwebforum

Altoida detects Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) up to ten years prior to onset using a tablet or smartphone – with 94% accuracy HOUSTON, Jan. 14, 2020 /PRNewswire/ -- Altoida, Inc. today announced that Chief Science Officer Ioannis Tarnanas has been...
May 30, 2019

Altoida Raises $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

HOUSTON, May 30, 2019 /PRNewswire/ -- Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of...
May 30, 2019

Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases

For the past nineteen years, Ioannis Tarnanas, the founder and chief scientific officer at Altoida, has been developing virtual and augmented reality tools to offer predictions about the onset of mental illness in older patients. The company, whose tools have been approved by the Food and Drug Admin…

Altoida Blogs

December 07, 2021

Cognitive Disorders and Mental Health: Building the Bridge to Better Support

Research into the connection between cognitive disorders and mental health will drive future approaches to holistic, personalized prevention and treatment.
December 02, 2021

Dementia’s Impact on Activities of Daily Living and Support for Long-Term Care

Understanding dementia’s impact on Activities of Daily Living is critical for informing providers on how to best care for and support dementia patients.
November 30, 2021

Refining Cognitive Function Assessment Tools To Better Support Physicians

There is an overwhelming need to refine cognitive function assessment tools to better support physicians in detecting impairment before symptom onset.
November 18, 2021

The Gut-Brain Health Connection and Alzheimer's Disease Link Drives Future Therapeutic Approaches

The link between the gut-brain health connection and Alzheimer’s disease may pave the way to future novel therapeutic approaches for treating the disease.
November 16, 2021

Patients Ask: Can Healthy Living Prevent Alzheimer’s Disease?

Can healthy living prevent Alzheimer’s disease? Current research suggests that lifestyle changes can significantly reduce the risk of disease development.
November 11, 2021

8 Early Signs of Alzheimer’s Disease in Young Adults

Early signs of Alzheimer’s disease in young adults include memory loss, difficulty planning and performing familiar tasks, and issues with problem-solving.
Show more

 Altoida Frequently Asked Questions

  • When was Altoida founded?

    Altoida was founded in 2016.

  • Who are Altoida key executives?

    Altoida's key executives are Richard Fischer, Ioannis Tarnanas and Maximilian Buegler.

  • How many employees does Altoida have?

    Altoida has 18 employees.

  • Who are Altoida competitors?

    Competitors of Altoida include Daval, Delft Imaging Systems and Solace Lifesciences.

  • Where is Altoida headquarters?

    Altoida headquarters is located at Professuren der Kultur-und Sozialwissenschaftlichen Fakultät 31 Hirschengraben, Luzern.

  • Where are Altoida offices?

    Altoida has offices in Luzern and Suwanee.

  • How many offices does Altoida have?

    Altoida has 2 offices.